Document is current
Any future updates will be listed below
-
Authors
Yip, Steven M.
Meyers, Daniel E.
Sisler, Jeff
Wycliffe-Jones, Keith
Kucharski, Edward
Elser, Christine
Temple-Oberle, Claire
Spadafora, Silvana
Ingledew, Paris-Ann
Giuliani, Meredith
Kuruvilla, Sara
Sumar, Nureen
Tam, Vincent C. https://orcid.org/0000-0001-8732-0530
-
Funding
Funding for this research was provided by:
Department of Oncology, University of Calgary (NA)
- License Information
-
More Information
Article History
Received: 28 August 2019
Accepted: 24 August 2020
First Online: 27 August 2020
Ethics approval and consent to participate
: Ethics approval was granted from Health Research Ethics Board of Alberta (HREBA) – Cancer Committee (CC) at the University of Calgary, Tom Baker Cancer Centre (Ethics ID: HREBA.CC-17-0096). Written consent was provided by participants who responded to and completed the survey.
: Not Applicable.
: Steven M. Yip: honoraria and/or consulting fees received from Janssen, Pfizer, Roche, BMS, Merck, AstraZeneca, Bayer, Hoffman-La Roche, and Novartis.Daniel E. Meyers: no competing interests.Jeff Sisler: no competing interests.Keith Wycliffe-Jones: no competing interests.Edward Kucharski: no competing interests.Christine Elser: no competing interests.Claire Temple-Oberle: no competing interests.Silvana Spadafora: no competing interests.Paris-Ann Ingledew: no competing interests.Meredith Giuliani: advisor AstraZeneca, research grant Eli Lilly, travel funding Elekta.Sara Kuruvilla: advisor and received honoraria from BMS, BI and Astrazeneca.Nureen Sumar: no competing interests.Vincent C. Tam: no competing interests.
